|
| Publications [#99804] of Bruce A Sullenger
Papers Published
- CP Rusconi, E Scardino, J Layzer, GA Pitoc, TL Ortel, D Monroe, BA Sullenger, RNA aptamers as reversible antagonists of coagulation factor IXa.,
Nature, vol. 419 no. 6902
(September, 2002),
pp. 90-4, ISSN 0028-0836 [doi]
(last updated on 2013/05/13)
Abstract:
Many therapeutic agents are associated with adverse effects in patients. Anticoagulants can engender acute complications such as significant bleeding that increases patient morbidity and mortality. Antidote control provides the safest means to regulate drug action. For this reason, despite its known limitations and toxicities, heparin use remains high because it is the only anticoagulant that can be controlled by an antidote, the polypeptide protamine. To date, no generalizable strategy for developing drug-antidote pairs has been described. We investigated whether drug-antidote pairs could be rationally designed by taking advantage of properties inherent to nucleic acids to make antidote-controlled anticoagulant agents. Here we show that protein-binding oligonucleotides (aptamers) against coagulation factor IXa are potent anticoagulants. We also show that oligonucleotides complementary to these aptamers can act as antidotes capable of efficiently reversing the activity of these new anticoagulants in plasma from healthy volunteers and from patients who cannot tolerate heparin. This generalizable strategy for rationally designing a drug-antidote pair thus opens up the way for developing safer regulatable therapeutics.
Keywords:
Anticoagulants • Antidotes • Base Sequence • Binding, Competitive • Drug Design* • Factor IXa • Factor VIIIa • Factor X • Heparin • Humans • Molecular Sequence Data • Nucleic Acid Conformation • Oligoribonucleotides • Partial Thromboplastin Time • Prothrombin Time • RNA • Thrombocytopenia • antagonists & inhibitors • antagonists & inhibitors* • chemically induced • chemistry • contraindications • drug effects • genetics • metabolism • pharmacology • pharmacology*
|
